Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation

Mehdizadeh, Mahshid; Parkhideh, Sayeh; Salari, Sina; Hajifathali, Abbas; Rezvani, Hamid; Mabani, Maryam

doi:10.31557/apjcp.2021.22.5.1639

Cited by 4 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The remaining three patients who had SAEs experienced either a single SAE, or two events of the same SAE. Despite this, the numbers seen here are higher than those found by prior studies with more conventional myeloablative preparative regimens, attributable to our small study population [ 10 , 11 ].…”

Section: Resultscontrasting

confidence: 92%

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide

Trunk,

Patel,

Prchal

et al. 2023

Leukemia Research Reports

View full text Add to dashboard Cite

Section: Resultscontrasting

confidence: 92%

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide

Trunk,

Patel,

Prchal

et al. 2023

Leukemia Research Reports

View full text Add to dashboard Cite

Busulfan/cyclophosphamide/fludarabine

2022

Reactions Weekly

View full text Add to dashboard Cite

A bioinspired supramolecular nanoprodrug for precision therapy of B-cell non-Hodgkin’s lymphoma

Zhang,

Tian,

Yang

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Fludarabine (FA) is still considered as a first-line chemotherapy drug for hematological tumors related to B lymphocytes. However, it is worth noting that the non-specific distribution and non-different cytotoxicity of FA may lead to irreversible consequences such as central nervous system damage such as blindness, coma, and even death. Therefore, it is very important to develop a system to targeting delivery FA. In preliminary studies, it was found that B lymphoma cells would specific highly expressing the sialic acid-binding immunoglobulin-like lectin 2 (known as CD22). Inspired by the specific recognition of sialic acid residues and CD22, we have developed a supramolecular prodrug based on polysialic acid, an endogenous biomacromolecule, achieving targeted-therapy of B-cell non-Hodgkin's lymphoma (B-NHL). Specifically, the prepared hydrophobic reactive oxygen species-responsive FA dimeric prodrug (F 2 A) interacts with the TPSA, which polysialic acid were modified by the thymidine derivatives, through noncovalent intermolecular interactions similar to "Watson-Crick" base pairing, resulting in the formation of nanoscale supramolecular prodrug (F@TPSA). Cell experiments have confirmed that F@TPSA can be endocytosed by CD22 + B lymphoma cells including Raji and Ramos cells, and there is a significant difference of endocytosis in other leukocytes. Furthermore, in B-NHL mouse model, compared with FA, F@TPSA is determined to have a stronger tumor targeting and inhibitory effect. More importantly, the distribution of F@TPSA in vivo tends to be enriched in lymphoma tissue rather than nonspecific, thus reducing the leukopenia of FA. The targeted delivery system based on PSA provides a new prodrug modification strategy for targeted treatment of B-NHL.

show abstract

Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation

Cited by 4 publications

References 20 publications

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide

Busulfan/cyclophosphamide/fludarabine

A bioinspired supramolecular nanoprodrug for precision therapy of B-cell non-Hodgkin’s lymphoma

Contact Info

Product

Resources

About